D A Kuban
Overview
Explore the profile of D A Kuban including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
231
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holliday E, Kuban D, Levy L, Bolukbasi Y, Master P, Choi S, et al.
Prostate Cancer Prostatic Dis
. 2017 May;
20(4):389-394.
PMID: 28462945
Background: Which men benefit most from adding androgen deprivation therapy (ADT) to salvage radiation therapy (SRT) after prostatectomy has not clearly been defined; therefore, we evaluated the impact of ADT...
2.
Cerne J, McGuire S, Grant S, Munsell M, Lee A, Kudchadker R, et al.
Prostate Cancer Prostatic Dis
. 2013 Aug;
16(4):346-51.
PMID: 23939133
Background: In prostate cancer patients treated with androgen deprivation therapy (ADT) and radiation therapy (RT), a pre-RT PSA level 0.5 ng ml(-1), determined after neoadjuvant ADT and before RT, predicts...
3.
Bian S, Kuban D, Levy L, Oh J, Castle K, Pugh T, et al.
Ann Oncol
. 2012 Feb;
23(9):2346-2352.
PMID: 22357249
Background: Dose-escalated (DE) radiation therapy (RT) and androgen deprivation therapy (ADT) improve prostate cancer outcomes over standard-dose RT. The benefit of adding ADT to DE-RT for men with intermediate-risk prostate...
4.
Thames H, DSouza W, Kuban D
Int J Radiat Biol
. 2003 Oct;
79(7):503-9.
PMID: 14530158
Dual interpretations are different radiobiological mechanisms that explain theoretically the same observed results. Radiobiological interpretations of the time factor are most frequently based on changes in total dose that produce...
5.
Taylor N, Kelly J, Kuban D, Babaian R, Pisters L, Pollack A
Int J Radiat Oncol Biol Phys
. 2003 Jun;
56(3):755-63.
PMID: 12788182
Purpose: The optimal role of radiotherapy (RT) to the prostate bed after radical prostatectomy (RP) is the subject of much debate. In this study, the results of adjuvant RT (ART)...
6.
Davis J, Kuban D, LYNCH D, Schellhammer P
J Urol
. 2001 Aug;
166(3):947-52.
PMID: 11490252
Purpose: Brachytherapy with 103palladium (103Pd) is an increasingly administered treatment modality for localized prostate cancer. We compared general and disease specific health related quality of life after 103Pd treatment, radical...
7.
Incognito L, Cazares L, Schellhammer P, Kuban D, Van Dyk E, Moriarty R, et al.
Int J Oncol
. 2000 Sep;
17(4):761-9.
PMID: 10995889
p53 gene mutations are among the most common specific genetic alterations in human cancer. Inactivation of p53 and subsequent protein accumulation has been implicated in a variety of human malignancies...
8.
Shipley W, Thames H, Sandler H, Hanks G, Zietman A, Perez C, et al.
JAMA
. 1999 May;
281(17):1598-604.
PMID: 10235152
Context: Prostate-specific antigen (PSA) evaluation leads to the early detection of both prostate cancer and recurrences following primary treatment. Prostate-specific antigen outcome information on patients 5 or more years following...
9.
Lawton C, Grignon D, Newhouse J, Schellhammer P, Kuban D
Radiographics
. 1999 Jan;
19(1):185-203.
PMID: 9925399
No abstract available.
10.
Kuban D, Schellhammer P
Semin Radiat Oncol
. 1998 Apr;
8(2):72-80.
PMID: 9516587
Pretreatment prostate-specific antigen (PSA) has been shown to be a powerful predictor of expected outcome after radiation for prostate cancer. Additional measures such as recursive partitioning analysis and PSA Cancer...